Xenofon Papanikolaou
YOU?
Author Swipe
View article: Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionals
Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionals Open
As multiple myeloma (MM) patients live longer, maintaining quality of life (QOL) has become an important treatment goal. However, the commonly used general quality of life questionnaires (QOLQs) were developed over 20 years ago. In this su…
View article: The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single‐Centre Experience
The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single‐Centre Experience Open
Background Radiotherapy (RT) is a well‐established treatment modality in multiple myeloma (MM), particularly for skeletal‐related events. However, its role is likely evolving with the introduction of modern systemic treatments. Methods We …
View article: Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single center, real-world experience
Bone-independent extramedullary disease is associated with inferior overall survival in multiple myeloma patients: a single center, real-world experience Open
Not available.
View article: Management of multiple myeloma presenting as malignant spinal cord compression during pregnancy: a case report
Management of multiple myeloma presenting as malignant spinal cord compression during pregnancy: a case report Open
not included as this is letter to the editor.
View article: Myeloid neoplasm post cytotoxic treatment in patients with multiple myeloma
Myeloid neoplasm post cytotoxic treatment in patients with multiple myeloma Open
View article: Outcomes of melphalan 140 mg/m<sup>2</sup> followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience
Outcomes of melphalan 140 mg/m<sup>2</sup> followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience Open
High‐dose melphalan followed by stem cell rescue is the standard consolidative therapy for transplant‐eligible patients with multiple myeloma (MM) in the United Kingdom. A melphalan dose of 200 mg/m 2 (Mel200) is considered the “gold stand…
View article: The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study
The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma—a single-centre, qualitative service evaluation study Open
View article: The impact of continuous lenalidomide maintenance treatment on people living with Multiple Myeloma – a single-centre, qualitative evaluation study
The impact of continuous lenalidomide maintenance treatment on people living with Multiple Myeloma – a single-centre, qualitative evaluation study Open
Purpose: Continuous lenalidomide maintenance treatment after autologous stem cell transplantation delivers improvement in progression free and overall survival among newly diagnosed multiple myeloma patients and has been the standard of ca…
View article: PB2108: SPINAL INVOLVEMENT IS ASSOCIATED WITH HIGH INCIDENCE OF SKELETAL RELATED EVENTS AND INFERIOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA. A SINGLE CENTRE EXPERIENCE IN 653 PATIENTS.
PB2108: SPINAL INVOLVEMENT IS ASSOCIATED WITH HIGH INCIDENCE OF SKELETAL RELATED EVENTS AND INFERIOR OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA. A SINGLE CENTRE EXPERIENCE IN 653 PATIENTS. Open
Background: Skeletal related events (pathological fractures, radiotherapy (XRT), spinal cord compression (SCC), surgical interventions (SI)) represent a frequent and debilitating complication of Multiple Myeloma (MM) with profound effect o…
View article: PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION
PB2091: DISPARITIES IN ENROLMENT INTO MULTIPLE MYELOMA CLINICAL TRIALS BY SOCIOECONOMIC DEPRIVATION Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Disparities in patients enrolled into clinical trials compared to real world populations have been reported, particularly with underrepresentation of different rac…
View article: Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience
Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience Open
High dose melphalan (HDM) followed by autologous stem cell transplantation (ASCT) remains the standard consolidation in transplant eligible multiple myeloma (MM) patients. The timing between HDM administration and hematopoietic stem cell r…
View article: Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Supplementary Table 1: Total Therapy 4 (TT4) protocol schema Supplementary Table 2: Adverse Events by Arm and Maximum NCI CTC Grade Supplementary Table 3: Top 51 gene probes distinguishing multiple myeloma with and without cytogenetic abno…
View article: Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Supplementary Figure 1: Consort flow diagram of patient flow through TT4 arms Supplementary Figure 2: Cumulative Incidence of Death and Post-Relapse Survival (P-values for S-TT4 vs L-TT4; TRM, p = 0.61; MRM, p = 0.70; OIM, p = 0.25). Suppl…
View article: Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Supplementary Figure 1: Consort flow diagram of patient flow through TT4 arms Supplementary Figure 2: Cumulative Incidence of Death and Post-Relapse Survival (P-values for S-TT4 vs L-TT4; TRM, p = 0.61; MRM, p = 0.70; OIM, p = 0.25). Suppl…
View article: Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Purpose: To determine whether a reduction in the intensity of Total Therapy (TT) reduces toxicity and maintains efficacy.Experimental Design: A total of 289 patients with gene expression profiling (GEP70)-defined low-risk mul…
View article: Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Purpose: To determine whether a reduction in the intensity of Total Therapy (TT) reduces toxicity and maintains efficacy.Experimental Design: A total of 289 patients with gene expression profiling (GEP70)-defined low-risk mul…
View article: Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants Open
Supplementary Table 1: Total Therapy 4 (TT4) protocol schema Supplementary Table 2: Adverse Events by Arm and Maximum NCI CTC Grade Supplementary Table 3: Top 51 gene probes distinguishing multiple myeloma with and without cytogenetic abno…
View article: Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real‐world multicentre <scp>UK</scp> retrospective analysis
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real‐world multicentre <span>UK</span> retrospective analysis Open
Summary Daratumumab, bortezomib and dexamethasone (DVd) is approved for patients with relapsed multiple myeloma following the CASTOR phase 3 clinical trial. This retrospective multicentre analysis assesses the overall response rate (ORR) a…
View article: Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma
Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma Open
Not available.
View article: The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study
The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study Open
View article: The Impact of COVID-19 on Autologous Stem Cell Transplantation in Multiple Myeloma A single-centre service evaluation
The Impact of COVID-19 on Autologous Stem Cell Transplantation in Multiple Myeloma A single-centre service evaluation Open
Autologous stem cell transplantation (ASCT) is standard of care in biologically fit, newly diagnosed multiple myeloma (MM) patients, offering better therapeutic outcomes and improved quality of life (QoL). However, with the UK’s 1st nation…
View article: Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors
Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors Open
Background Plasma cell disorders (PCD) are at risk of inadequate immune responses to COVID-19 vaccines due to recognised humoral and cellular immune dysfunction which is multi-factorial and related to host and disease factors. With an esti…
View article: Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors Open
We read with interest Avivi et al.1 evaluating humoral response to two doses of BNT162b2 mRNA vaccine in multiple myeloma (MM) at manufacturer's dosing interval. Suboptimal response to one2-4 and both doses5 of coronavirus disease 2019 (CO…
View article: OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines
OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines Open
View article: Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy
Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy Open
Patients with multiple myeloma and related plasma cell disorders (PCD) are considered extremely vulnerable to SARS-CoV-2 infection due to disease-related impaired humoral and cellular immunity as well as receipt of immunosuppressive therap…
View article: Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma Open
Background The treatment paradigm for multiple myeloma (MM) continues to evolve with the development of novel therapies and the earlier adoption of continuous treatments into the treatment pathway. Lenalidomide-refractory patients now repr…
View article: Successful use of allogeneic bone marrow transplantation in a patient with myelodysplastic syndrome presenting with autoimmune manifestations
Successful use of allogeneic bone marrow transplantation in a patient with myelodysplastic syndrome presenting with autoimmune manifestations Open
Myelodysplastic syndrome (MDS) is a clonal haematopoietic disorder, characterised by ineffective haematopoiesis and peripheral-blood cytopenias.1 There is a widely recognised association of MDS with autoimmune symptoms, with an incidence r…
View article: A rare case of relapsed multiple myeloma with aberrant T‐cell antigen expression and skin plasmacytomas
A rare case of relapsed multiple myeloma with aberrant T‐cell antigen expression and skin plasmacytomas Open
This 60-year-old gentleman was first diagnosed with non-secretory multiple myeloma (MM) with extensive skeletal lytic lesions in March 2017. The t(11;14)(q13;q32) IgH/CCND1 translocation was detected by interphase fluorescence in situ hybr…
View article: DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation
DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation Open
Routine use of novel agents to treat newly diagnosed and relapsed multiple myeloma (MM) produces high response rates and improved survival. However, 15–20% of patients have suboptimal responses and their management remains challenging.1 Tr…
View article: Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design Open